Safety and Activity of Nivolumab Monotherapy in Advanced and Metastatic Gastric or Gastroesophageal Junction Cancer (GC/GEC): Results From the CheckMate-032 Study

Dung T. Le1, Johanna Bendell2, Emiliano Calvo3, Joseph Kim4, Paolo Ascierto5, Padmanee Sharma6, Patrick A. Ott7, Pietri Bono8, Dirk Jaeger9, Jeffrey Evans10, Filippo de Braud11, Ian Chau12, Marina Tschalik13, Christopher T. Harbison14, Chen-Sheng Lin15, Yelena Y. Janjigian16

1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; 3Hospital Clínico San Carlos, Madrid, Spain; 4F. Hoffmann-La Roche Ltda, Basel, Switzerland; 5Medical Oncology Research Institute, Nishinomiya, Japan; 6Comprehensive Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA; 7University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; 8California Cancer Institute, Oakland, CA, USA; 9National Cancer Institute of Canada, Ottawa, Canada; 10Bristol-Myers Squibb, Princeton, NJ, USA; 11Eisai, Tokyo, Japan; 12Southeastern Cancer System, Chattanooga, TN, USA; 13Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 14MD Anderson Cancer Center, Houston, TX, USA; 15Comprehensive Cancer Center, University of Heidelberg, Heidelberg, Germany; 16Boston Work of United Cancer Centers, University of Glasgow, Glasgow, UK; 17Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 18Royal Marsden Hospital, London and Surrey, UK; 19Kristal-Max Squibb, Princeton, NJ, USA; 20Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Background

• Patients with advanced or metastatic gastric or gastroesophageal junction cancer who have failed one or more prior systemic therapies for gastric or gastroesophageal junction cancer are eligible for participation

Methods

• Patients were randomized 1:1:1 to receive nivolumab (3 mg/kg) every 2 weeks (Q2W), nivolumab (1 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks (Q3W) for 4 cycles, or both drugs together every 3 weeks

Results

• Patient demographics and disease characteristics were well balanced across treatment arms

Conclusions

• Nivolumab, alone or in combination with ipilimumab, had manageable toxicity

References

• Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be distributed or published without the author’s permission

Acknowledgments

• Presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA, USA

Figure 1. Overall Survival

Figure 2. Best Overall Response

Figure 3. Best Overall Response

Figure 4. Disease Control Rate

Figure 5. Change From Baseline in Target Lesion Size Over Time

Figure 6. Overall Survival